Posted by Michael Wonder on 21 Jun 2018
Health Canada approves Taltz (ixekizumab) for treatment of active psoriatic arthritis
20 June 2018 - The approval of Taltz is based on the Phase 3 clinical trials that demonstrated efficacy on both joints and skin symptoms.
Eli Lilly announced that Health Canada has approved Taltz (ixekizumab) for the treatment of adult patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARD). It can be used alone or in combination with a conventional DMARD, such as methotrexate.
Taltz was granted a Notice of Compliance on March 29, 2018 based on results from the pivotal SPIRIT-P1 and SPIRIT-P2 clinical trials. Taltz was first approved in Canada in 2016 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
